ID
OREX

Integral Derivatives’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Integral Derivatives’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-1,223
Closed -$74K – 1631
2014
Q4 		$74K Sell
1,223
-1,480
-55% -$74.3K ﹤0.01% 1316
2014
Q3 		$115K Buy
+2,703
New +$145K ﹤0.01% 1320

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Integral Derivatives's OREX Position: Q1 2015 in Review

Integral Derivatives sold out of Orexigen Therapeutics, Inc. (OREX) in Q1 2015, closing a stake of 1,223 shares — an estimated $74K sold.

Integral Derivatives first reported a position in OREX in Q3 2014 and held it in 2 quarters. The position peaked at $115K in Q3 2014. 160 funds tracked by Wall St. Rank hold OREX as of Q1 2015.

  • Integral Derivatives reported no remaining Orexigen Therapeutics, Inc. position as of Q1 2015 after selling out during the quarter.
  • Integral Derivatives sold 1,223 Orexigen Therapeutics, Inc. shares in Q1 2015, an estimated $74K.
  • Integral Derivatives first reported a position in Orexigen Therapeutics, Inc. in Q3 2014 and held it in 2 quarters.
  • Integral Derivatives's Orexigen Therapeutics, Inc. position peaked at $115K in Q3 2014.
  • 160 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q1 2015.

Based on Integral Derivatives's 13F filing for Q1 2015, filed 20 Apr 2015.